LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

CareDx Inc

Geschlossen

BrancheGesundheitswesen

13.44 0.83

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.19

Max

13.55

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.8M

-8.6M

Verkäufe

2M

87M

KGV

Branchendurchschnitt

13.01

35.733

Gewinnspanne

-9.885

Angestellte

644

EBITDA

9.3M

-4M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+38.42% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

3. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

26M

727M

Vorheriger Eröffnungskurs

12.61

Vorheriger Schlusskurs

13.44

Nachrichtenstimmung

By Acuity

30%

70%

87 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

CareDx Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Sept. 2025, 23:37 UTC

Heiße Aktien

Stocks to Watch: Oracle, Wearable Devices, GameStop

9. Sept. 2025, 20:41 UTC

Ergebnisse

Oracle's Backlog Surges With Major Customer Deals in 1Q

9. Sept. 2025, 20:30 UTC

Ergebnisse

GameStop 2Q Sales, Profit Rise

9. Sept. 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9. Sept. 2025, 21:35 UTC

Ergebnisse

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 21:32 UTC

Ergebnisse

Oracle's Backlog Swells With Big Customer Deals -- Update

9. Sept. 2025, 21:02 UTC

Akquisitionen, Fusionen, Übernahmen

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Sept. 2025, 20:33 UTC

Ergebnisse

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9. Sept. 2025, 20:26 UTC

Ergebnisse

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 20:23 UTC

Ergebnisse

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 20:12 UTC

Ergebnisse

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9. Sept. 2025, 20:10 UTC

Ergebnisse

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9. Sept. 2025, 20:10 UTC

Ergebnisse

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9. Sept. 2025, 20:09 UTC

Ergebnisse

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9. Sept. 2025, 20:09 UTC

Ergebnisse

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle 1Q Operating Income Was $4.3 B >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9. Sept. 2025, 20:07 UTC

Ergebnisse

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9. Sept. 2025, 20:06 UTC

Ergebnisse

Oracle 1Q Software Revenue $5.72B >ORCL

9. Sept. 2025, 20:06 UTC

Ergebnisse

Synopsys 3Q Adj EPS $3.39 >SNPS

9. Sept. 2025, 20:06 UTC

Ergebnisse

Oracle 1Q Cloud Revenue $7.19B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Rev $14.93B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q EPS $1.01 >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Synopsys 3Q EPS $1.50 >SNPS

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Services Revenue $1.35B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Adj EPS $1.47 >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Hardware Revenue $670M >ORCL

Peer-Vergleich

Kursveränderung

CareDx Inc Prognose

Kursziel

By TipRanks

38.42% Vorteil

12-Monats-Prognose

Durchschnitt 19.13 USD  38.42%

Hoch 28 USD

Tief 12.5 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CareDx Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

3

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

14.77 / 18.49Unterstützung & Widerstand

Kurzfristig

Neutral Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

87 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat